Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna - Italia; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna - Italia; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
Clin Genitourin Cancer. 2024 Jun;22(3):102074. doi: 10.1016/j.clgc.2024.102074. Epub 2024 Mar 18.
Penile squamous cell carcinoma (PSCC) is a rare tumor with an aggressive behavior. The Meet-URO 23/I-RARE registry includes rare genitourinary malignancies. We extracted patients with PSCC to conduct a retrospective study aimed at assessing clinical outcomes and prognostic factors.
Primary endpoints were overall survival and progression-free survival. Prognostic factors for OS and PFS were analyzed using univariate and multivariate analysis. From the Meet-URO 23/I-RARE database, we extracted 128 patients with diagnosis of PSCC. About 48% of patients underwent first-line of therapy.
In the overall population, median OS from diagnosis was 34.6 months. Significant differences in median OS were observed according to ECOG PS at diagnosis (57.3 months vs. 8.3 months; P < .001), and median age (≤77y 88.8 months vs. >77y 26 months; P = .013). At multivariate analysis, ECOG PS 2-4 at diagnosis (HR 3.04) and lymph node metastases (HR 2.49) were independently associated with a higher risk of death. Among patients undergoing first-line therapy (n = 61), median OS was 12.3 months, and a statistically significant difference was found according to type of response to first-line (DCR 24.4 months vs. PD 7.1 months; P < .001). Multivariate analysis showed that only age >77 years was associated with a worse OS (HR 2.16). A statistically significant difference in PFS was found according to platinum plus 5-fluorouracil versus platinum plus taxane (4.9 vs. 3.4 months; P = .036) and regimens with 2 versus 3 drugs (3.4 vs. 8.6 months; P = .019). At the multivariate analysis only regimens with platinum plus taxane were associated with worse PFS (HR 2.83).
In our registry study, PSCC is confirmed to be an aggressive disease. Poor ECOG PS, presence of lymph node metastases, and higher age at diagnosis appear to be associated with worse survival outcomes.
阴茎鳞状细胞癌（PSCC）是一种具有侵袭性行为的罕见肿瘤。Meet-URO 23/I-RARE 登记处包括罕见的泌尿生殖系统恶性肿瘤。我们提取了患有 PSCC 的患者进行回顾性研究，旨在评估临床结果和预后因素。
主要终点是总生存期和无进展生存期。使用单因素和多因素分析来分析 OS 和 PFS 的预后因素。从 Meet-URO 23/I-RARE 数据库中，我们提取了 128 名诊断为 PSCC 的患者。约 48%的患者接受了一线治疗。
在总体人群中，从诊断到中位 OS 为 34.6 个月。根据诊断时 ECOG PS（57.3 个月比 8.3 个月；P<.001）和中位年龄（≤77y 88.8 个月比>77y 26 个月；P=.013），OS 存在显著差异。多因素分析显示，诊断时 ECOG PS 2-4（HR 3.04）和淋巴结转移（HR 2.49）与死亡风险增加独立相关。在接受一线治疗的患者中（n=61），中位 OS 为 12.3 个月，根据一线治疗的反应类型（DCR 24.4 个月比 PD 7.1 个月；P<.001），发现存在统计学差异。多因素分析显示，只有年龄>77 岁与 OS 较差相关（HR 2.16）。根据铂类加 5-氟尿嘧啶与铂类加紫杉烷（4.9 比 3.4 个月；P=.036）以及 2 种药物与 3 种药物的方案（3.4 比 8.6 个月；P=.019），发现 PFS 存在统计学差异。多因素分析显示，只有铂类加紫杉烷的方案与较差的 PFS 相关（HR 2.83）。
在我们的登记研究中，PSCC 被确认为一种侵袭性疾病。较差的 ECOG PS、存在淋巴结转移和诊断时年龄较大似乎与较差的生存结果相关。
